Responsable des Activités de Pharmacologie/Immunologie Clinique Société biopharmaceutique à taille humaine développant des produits innovants d’immunothérapie…
January 8 – 11, 2018 J.P. Morgan 36th Annual Healthcare Conference 2018 San-Francisco The annual J.P. Morgan Healthcare Conference is the largest and most…
Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…
Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux Paris, le 12…
Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…
Invectys will attend to the 18th annual BIO€QUITY Europe Meet Invectys there ! More information: invest@invectys.com 18TH ANNUAL BIO€QUITY EUROPE Bio€quity…
Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer…
Invectys attend ASCO 2017 meeting in Chicago Invectys will be at the Annual Meeting is organized by American Society Of Clinical Oncology (ASCO). This meeting…
